The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines
- PMID: 24338765
- PMCID: PMC3980041
- DOI: 10.1007/s13277-013-1465-9
The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines
Abstract
In response to ionizing radiation, several signaling cascades in the cell are activated to repair the DNA breaks, prevent apoptosis, and keep the cells proliferating. AKT is important for survival and proliferation and may also be an activating factor for DNA-PKcs and MRE11, which are essential proteins in the DNA repair process. AKT (PKB) is hyperactivated in several cancers and is associated with resistance to radiotherapy and chemotherapy. There are three AKT isoforms (AKT1, AKT2, and AKT3) with different expression patterns and functions in several cancer tumors. The role of AKT isoforms has been investigated in relation to radiation response and their effects on DNA repair proteins (DNA-PKcs and MRE11) in colon cancer cell lines. The knockout of AKT1 and/or AKT2 affected the radiation sensitivity, and a deficiency of both isoforms impaired the rejoining of radiation-induced DNA double strand breaks. Importantly, the active/phosphorylated forms of AKT and DNA-PKcs associate and exposure to ionizing radiation causes an increase in this interaction. Moreover, an increased expression of both DNA-PKcs and MRE11 was observed when AKT expression was ablated, yet only DNA-PKcs expression influenced AKT phosphorylation. Taken together, these results demonstrate a role for both AKT1 and AKT2 in radiotherapy response in colon cancer cells involving DNA repair capacity through the nonhomologous end joining pathway, thus suggesting that AKT in combination with DNA-PKcs inhibition may be used for radiotherapy sensitizing strategies in colon cancer.
Figures






Similar articles
-
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.Mol Cancer Ther. 2008 Jul;7(7):1772-81. doi: 10.1158/1535-7163.MCT-07-2200. Mol Cancer Ther. 2008. PMID: 18644989
-
PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation.Oncogene. 2011 Feb 24;30(8):944-55. doi: 10.1038/onc.2010.467. Epub 2010 Oct 18. Oncogene. 2011. PMID: 20956948
-
MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks.Cell Cycle. 2011 Jul 1;10(13):2218-32. doi: 10.4161/cc.10.13.16305. Epub 2011 Jul 1. Cell Cycle. 2011. PMID: 21623170
-
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.Semin Cancer Biol. 2015 Dec;35:180-90. doi: 10.1016/j.semcancer.2015.07.003. Epub 2015 Jul 17. Semin Cancer Biol. 2015. PMID: 26192967 Review.
-
Targeting AKT/PKB to improve treatment outcomes for solid tumors.Mutat Res. 2020 Jan-Apr;819-820:111690. doi: 10.1016/j.mrfmmm.2020.111690. Epub 2020 Feb 20. Mutat Res. 2020. PMID: 32120136 Free PMC article. Review.
Cited by
-
Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis.Front Oncol. 2023 Jul 6;13:1129682. doi: 10.3389/fonc.2023.1129682. eCollection 2023. Front Oncol. 2023. PMID: 37483521 Free PMC article.
-
Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study.Mol Med. 2022 Sep 6;28(1):105. doi: 10.1186/s10020-022-00520-6. Mol Med. 2022. PMID: 36068491 Free PMC article.
-
Akt isoform specific effects in ovarian cancer progression.Oncotarget. 2016 Nov 15;7(46):74820-74833. doi: 10.18632/oncotarget.11204. Oncotarget. 2016. PMID: 27533079 Free PMC article.
-
Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination.Int J Mol Sci. 2019 Dec 14;20(24):6316. doi: 10.3390/ijms20246316. Int J Mol Sci. 2019. PMID: 31847370 Free PMC article.
-
RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.Oncogene. 2016 Dec 8;35(49):6319-6329. doi: 10.1038/onc.2016.163. Epub 2016 May 16. Oncogene. 2016. PMID: 27181206 Free PMC article.
References
-
- Krishnan S, Janjan N, Skibber J, Rodriguez-Bigas M, Wolff R, Das P, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006;66(3):762–771. doi: 10.1016/j.ijrobp.2006.05.063. - DOI - PubMed
-
- Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998;58(16):3579–3585. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous